AIP
TRDA icon

Ameritas Investment Partners’s Entrada Therapeutics TRDA Stock Holding History

Ameritas Investment Partners’s Portfolio TRDA Stock Details TRDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$30.5K Hold
2,417
– – ﹤0.01% 2375
2025
Q4 		$24.8K Hold
2,417
– – ﹤0.01% 2529
2025
Q3 		$14K Hold
2,417
– – ﹤0.01% 2836
2025
Q2 		$16.2K Hold
2,417
– – ﹤0.01% 2748
2025
Q1 		$21.9K Hold
2,417
– – ﹤0.01% 2514
2024
Q4 		$41.8K Hold
2,417
– – ﹤0.01% 2291
2024
Q3 		$38.6K Buy
2,417
+650
+37% +$10.2K ﹤0.01% 2341
2024
Q2 		$25.2K Hold
1,767
– – ﹤0.01% 2517
2024
Q1 		$25K Hold
1,767
– – ﹤0.01% 2473
2023
Q4 		$26.7K Hold
1,767
– – ﹤0.01% 2456
2023
Q3 		$27.9K Hold
1,767
– – ﹤0.01% 2388
2023
Q2 		$26.8K Buy
+1,767
New +$24.3K ﹤0.01% 2407
2022
Q2 		– Sell
-708
Closed -$7K – 3233
2022
Q1 		$7K Hold
708
– – ﹤0.01% 2901
2021
Q4 		$12K Buy
+708
New +$17.2K ﹤0.01% 2847

Other funds holding TRDA

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $360M AUM 345.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
MC
Merck & Co Kenilworth, New Jersey $349M AUM 146.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SG
StepStone Group La Jolla, California $207M AUM 12.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Ameritas Investment Partners's TRDA Position: Q1 2026 in Review

Ameritas Investment Partners held its Entrada Therapeutics (TRDA) position steady in Q1 2026 at 2,417 shares worth $30.5K. The position accounts for ﹤0.01% of the portfolio, ranked #2375.

Ameritas Investment Partners first reported a position in TRDA in Q4 2021 and has held it in 14 quarters since. The position peaked at $41.8K in Q4 2024. 120 funds tracked by Wall St. Rank hold TRDA as of Q1 2026.

  • Ameritas Investment Partners held 2,417 shares of Entrada Therapeutics worth $30.5K as of Q1 2026.
  • Ameritas Investment Partners left its Entrada Therapeutics share count unchanged in Q1 2026.
  • Entrada Therapeutics made up ﹤0.01% of Ameritas Investment Partners's portfolio in Q1 2026, its #2375 holding.
  • Ameritas Investment Partners first reported a position in Entrada Therapeutics in Q4 2021 and has held it in 14 quarters since.
  • Ameritas Investment Partners's Entrada Therapeutics position peaked at $41.8K in Q4 2024.
  • 120 funds tracked by Wall St. Rank held Entrada Therapeutics as of Q1 2026.

Based on Ameritas Investment Partners's 13F filing for Q1 2026, filed 13 May 2026.